IntoCell
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Shinildong-ro Daedeok-gu, Daejeon, 3...Phone Number
+82 427160083Website
www.intocell.co.krRevenue
$11 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IntoCell
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel ADC platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. In addition to its OHPAS linker, the company has also successfully developed and tested its own proprietary benzodiazepines (BD) to overcome the challenges of existing BD toxins including their lack of conjugatable functional groups and their poor aqueous solubility. IntoCell is currently seeking research and development partners interested in licensing its ADC platform technologies. It is open to discussing exploratory pilot and feasibility studies for its cleavage chemistry focused linker technology and its novel benzodiazepine payloads.Explore more
IntoCell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IntoCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on IntoCell recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once IntoCell has new funding data
Click to see if IntoCell had a recent Job posting/layoffs
IntoCell, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at IntoCell
Product Launch: Get notified when IntoCell launches new products
Check out if IntoCell is spiking on competitors!
Check if IntoCell has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined IntoCell as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
IntoCell is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
IntoCell is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IntoCell.
IntoCell Tech Stack
A closer look at the technologies used by IntoCell
See more technologies
IntoCell News & Media
Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field. Leveraging IntoCell's proprietary drug-linker technologies alongside its formidable 20-year experience in ADC development and manufacture, Piramal...Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field. Leveraging IntoCell's proprietary drug-linker technologies alongside its formidable 20-year experience in ADC development and manufacture, Piramal...WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform technologies, announced today that they have signed a Memorandum of Understanding (MOU) for a comprehensive partnership in drug-linker technology and CRDMO services spanning from discovery to commercialization. UnderWuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IntoCell
Sign Up For FreeTo access detailed company insights
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel ADC platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. In addition to its OHPAS linker, the company has also successfully developed and tested its own proprietary benzodiazepines (BD) to overco... Read More
